Results are in for a new depression drug trial, and they’re cratering this stock

Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, fell short of expectations in a late-stage clinical trial, disappointing Wall Street.

Read more…

​Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, fell short of expectations in a late-stage clinical trial, disappointing Wall Street.Read more…